Since post-translational modifications of proteins may have an impact on the pathogenesis of diseases like atherosclerosis, diabetes mellitus and chronic kidney disease (CKD), post-translational modifications are currently gaining increasing interest. In this study, a comprehensive method for analysis of these post-translational modifications is established for the clinical diagnostic routine. METHODS: Here, we analysed albumin -the most abundant plasma protein in humanisolated from CKD patients and healthy controls by chromatographic steps and identified by MALDI mass-spectrometry. Post-translational modifications of albumin were identified after digestion by analysing mass-signal shifts of albumin peptides using pertinent mass-databases. RESULTS: Albumin isolated from plasma of CKD patients but not from healthy control subjects was specifically post-translationally modified by guanidylation of lysines at positions 249, 468, 548, 565 and 588. After identification of guanidylations as posttranslational modifications of albumin isolated from CKD patients, these modifications were quantified by mass-spectrometry demonstrating a significant increase in the corresponding mass-signal intensities in CKD patients compared to healthy controls. The relative amount of guanidylation of lysine at position 468 in CKD patients was determined as 63 6 32 % (N¼3). Subsequently, we characterized the pathophysiological impact of the post-translational guanidylation on the binding capacity of albumin for representative hydrophobic metabolic waste products. In-vitro guanidylation of albumin from healthy control subjects caused a decreased binding capacity of albumin in a time-dependent manner. Binding of indoxyl sulfate (protein bound fraction) decreased from 82 6 1 % of non post-translationally modified albumin to 56 6 1 % after in-vitro guanidylation (p < 0.01) whereas the binding of tryptophan decreased from 20 to 4%. These results are in accordance with the binding of indoxyl sulfate to albumin from healthy control subjects and CKD patients (88 6 3 vs. 74 6 10, p < 0.01). Thus, in-vitro post-translational guanidylation of albumin had a direct effect on the binding capacity of hydrophobic metabolites like indoxyl sulfate and tryptophan. CONCLUSIONS: We used a mass spectrometry-based method for the characterisation of post-translational modification and demonstrated the pathophysiological impact of a representative post-translational modification of plasma albumin. The data described in this study may help to elucidate the pathophysiological role of protein modifications. is an efficacious and well-tolerated phosphate binder. We aimed to evaluate the effect of this iron-based phosphate binding agent on renal function, mineral homeostasis and vascular calcification in a rat model with adenineinduced CKD and vascular calcifications. METHODS: To induce stable CKD, 64 male Wistar rats were administered a 0.25% adenine enriched diet with a low vitamin K content (0.25% adenine, 0.2 mg/kg Vitamin K, 1% Ca, 1% P, 1 IU/g vitamin D and 6% protein) during the entire study period of 8 weeks. CKD rats were randomly assigned to 4 treatment groups: (i) vehicle (n¼16), (ii) 2.5 g/kg/day PA21 (n¼16), (iii) 5.0 g/kg/day PA21 (n¼16) and (iv) 3.0 g/ kg/day CaCO 3 (n¼16). Evolution in renal function and mineral metabolism was followed at regular time points by measurement of serum creatinine, phosphorus and calcium. Ionized calcium, hematocrit, hemoglobin, pH and bicarbonate, were measured using an i-STAT 1 Point-of-Care analyzer immediately at the time of blood sampling. Calcification in the aorta, femoral and carotid artery was assessed by determining the calcium content via flame atomic absorption spectrometry. RESULTS: Vehicle treated CKD rats developed severe renal impairment, with creatinine values around 3.5-4 mg/dL, and anemia as indicated by decreased serum hematocrit and hemoglobin levels. CKD went along with development of hyperphosphatemia and hypocalcemia. CKD rats treated with 2.5 or 5 g/kg PA21 resulted in significant lower serum creatinine and phosphorus levels and higher ionized calcium levels after 8 weeks of daily treatment as compared to vehicle treated CKD rats. The better preserved renal function with PA21 treatment was also reflected in parameters of anemia which
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CONCLUSIONS:
Treatment with the iron-based phosphate binder PA21 had, aside from its phosphate lowering capacity, a beneficial impact on the development towards severe CKD and anemia. Calcification in the aorta and peripheral arteries was significantly reduced by PA21 treatment. Nephrologisches Zentrum, Klinikum der Universit€ at München, Medizinische Klinik und Poliklinik IV, Munich, Germany INTRODUCTION AND AIMS: Despite profound hyperuricemia, CKD and ESRD patients rarely develop gouty arthritis, but why? Gout is thought to develop from the formation of monosodium urate (MSU) crystals triggering an acute inflammatory response associated with neutrophil extracellular traps (NET) and activation of monocytes/macrophages in the affected joints and tissues. We hypothesized that some uremic toxin acts as an inhibitor of crystal-induced NET formation and monocyte activation, and speculated on a suppressive effect of soluble uric acid (UA) in this context. METHODS: Human blood neutrophils and CD14þ monocytes were isolated from CKD stage 2-4 (n¼10) and CKD stage 5 (n¼18) patients or healthy controls (CKD stage 0) (n¼8). Monocytes were stimulated either with LPS, MSU crystals or soluble UA alone or in combination for gene expression profiling using RT-PCR, and for intracellular cytokine production via flow cytometry. Serum from healthy controls and CKD stage 5 patients was pretreated with or without Rasburicase, and then added to healthy monocytes prior to MSU crystal or LPS stimulation. Supernatants from activated monocytes were collected and added to the neutrophil culture for 3 hours, and 
